Skip To Content

Insys Therapeutics, Inc. Securities Litigation

(866) 905-8102

This official website is maintained by the Claims Administrator under the supervision of Class Counsel in the action titled Richard Di Donato v. Insys Therapeutics, Inc., et al., No. 16-cv-00302-NVW (the "Action"), pending in the United States District Court for the District of Arizona.

Insys Therapeutics, Inc. Securities Litigation

ALL PERSONS AND ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED INSYS THERAPEUTICS, INC. (“INSYS”) COMMON STOCK DURING THE PERIOD FROM MARCH 3, 2015, THROUGH JANUARY 25, 2016, AND WERE DAMAGED THEREBY.

If you are a member of the Class, you are subject to the settlements reached with Defendant Darryl S. Baker, Defendant John N. Kapoor, and Defendant Michael L. Babich in the Action. The Class certified by the Court on September 20, 2019 consists of:


All persons and entities who purchased or otherwise acquired Insys Therapeutics, Inc. (“Insys”) common stock during the period from March 3, 2015, through January 25, 2016, and were damaged thereby.

 

Excluded from the Class are: (a) Defendants; (b) present and former directors or executive officers of Insys and members of their immediate families (as defined in 17 C.F.R. § 229.404, Instructions (1)(a)(iii) and (1)(b)(ii)); (c) any of the foregoing individuals’ or entities’ legal representatives, heirs, successors, or assigns; and (d) any entity in which any Defendant has or had a controlling interest, or which is related to or affiliated with any Defendant.

 

For more information about the settlement with Defendant Darryl S. Baker, click here.

 

For more information about the settlement with Defendant John N. Kapoor, click here.

 

For more information about the settlement with Defendant Michael L. Babich, click here.

 

If you have any questions, you may call the Insys Therapeutics, Inc. Securities Litigation Help Line at 866-905-8102 or email info@InsysRXSecuritiesLitigation.com.